Viking Therapeutics announced that data from the company’s Phase 1 single ascending dose, or SAD, and multiple ascending dose, or MAD, clinical trial of VK2735 will be highlighted as part of an oral presentation at ObesityWeek 2023, the annual meeting of The Obesity Society. VK2735 is a novel dual agonist of the glucagon-like peptide 1, or GLP-1, and glucose-dependent insulinotropic polypeptide, or GIP, receptors in development for the potential treatment of various metabolic disorders such as obesity. ObesityWeek 2023 is being held October 14-17 at the Kay Bailey Hutchison Convention Center in Dallas, Texas. The oral presentation will provide an overview of previously reported results from Viking’s Phase 1 SAD/MAD study of VK2735 in healthy volunteers with a BMI greater than or equal to30. In addition, new findings related to the impact of VK2735 on subjects’ liver fat content and plasma lipid levels will be reported.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on VKTX:
- Viking Therapeutics call volume above normal and directionally bullish
- Viking Therapeutics recent 50% selloff ‘excessive,’ says William Blair
- Biotech Alert: Searches spiking for these stocks today
- Unusually active option classes on open September 15th
- VK2735 could be ‘significant value driver’ for Viking, says H.C. Wainwright